Neutralizing tumor growth in embryonic stem cell therapy

May 06, 2009

Researchers at the Hebrew University of Jerusalem have discovered a method to potentially eliminate the tumor-risk factor in utilizing human embryonic stem cells.

Their work paves the way for further progress in the promising field of .

Human embryonic stem cells are theoretically capable of differentiation to all cells of the mature (and are hence defined as "pluripotent"). This ability, along with the ability to remain undifferentiated indefinitely in culture, make regenerative medicine using human embryonic stem cells a potentially unprecedented tool for the treatment of various diseases, including diabetes, Parkinson's disease and heart failure.

A major drawback to the use of stem cells, however, remains the demonstrated tendency of such cells to grow into a specific kind of tumor, called teratoma, when they are implanted in laboratory experiments into mice. It is assumed that this tumorigenic feature will be manifested upon transplantation to human patients as well. The development of tumors from embryonic stem cells is especially puzzling given that these cells start out as completely normal cells.

A team of researchers at the Stem Cell Unit in the Department of Genetics at the Silberman Institute of Life Sciences at the Hebrew University has been working on various approaches to deal with this problem.

In their latest project, the researchers analyzed the of tumor formation from human embryonic stem cells and identified a key gene that is involved in this unique tumorigenicity. This gene, called survivin, is expressed in most cancers and in early stage embryos, but it is almost completely absent from mature normal tissues.

The survivin gene is especially highly expressed in undifferentiated human and in their derived tumors. By neutralizing the activity of survivin in the undifferentiated cells as well as in the tumors, the researchers were able to initiate programmed cell death (apoptosis) in those cells.

This inhibition of this gene just before or after transplantation of the cells could minimize the chances of tumor formation, but the researchers caution that a combination of strategies may be needed to address the major safety concerns regarding tumor formation by human embryonic .

Source: Hebrew University of Jerusalem (news : web)

Explore further: A novel therapy for sepsis?

add to favorites email to friend print save as pdf

Related Stories

Study: Skin cells turned into stem cells

Aug 22, 2005

The controversy over embryonic stem cell research may become moot with a procedure that turns skin cells into what appear to be embryonic stem cells.

New study hopeful on neural stem cells

Aug 05, 2006

Neural stem cells derived from federally approved human embryonic cells are inferior to stem cells derived from donated fetal tissue, a new study found.

Forever young: Differentiation blocked in tumor stem cells

Jan 07, 2008

A new comparison of normal stem cells and cancer stem cells reveals that the cancer stem cells are abnormally trapped at an early stage of development. The research, published by Cell Press in the January issue of Cancer Ce ...

Recommended for you

A novel therapy for sepsis?

8 hours ago

A University of Tokyo research group has discovered that pentatraxin 3 (PTX3), a protein that helps the innate immune system target invaders such as bacteria and viruses, can reduce mortality of mice suffering ...

Cellular protein may be key to longevity

Sep 15, 2014

Researchers have found that levels of a regulatory protein called ATF4, and the corresponding levels of the molecules whose expression it controls, are elevated in the livers of mice exposed to multiple interventions ...

Gut bacteria tire out T cells

Sep 15, 2014

Leaky intestines may cripple bacteria-fighting immune cells in patients with a rare hereditary disease, according to a study by researchers in Lausanne, Switzerland. The study, published in The Journal of Experimental Me ...

User comments : 0